Alpha GPC (L-alpha-glycerylphosphorylcholine) is a glycerophosphocholine ester that breaks down into choline (feeding acetylcholine synthesis) and a glycerophosphate fraction. CDP-Choline (Citicoline, cytidine diphosphocholine) is a naturally occurring Kennedy-pathway intermediate that hydrolyzes into choline plus cytidine — with cytidine subsequently converted to uridine and studied for its role in phospholipid synthesis and brain energy metabolism (Adibhatla & Hatcher 2005).

Alpha GPC. The review literature reports Alpha GPC contains approximately 41% choline by weight, one of the highest choline densities among commonly studied choline-donor compounds (Li et al., J Food Sci 2025). CDP-Choline contributes choline as part of a larger molecule that also includes cytidine, so its per-mass choline delivery is lower — but its cytidine/uridine fraction feeds a separate phospholipid-synthesis pathway not accessed by Alpha GPC in the same way.

Yes. Both Alpha GPC and CDP-Choline are reported in the peer-reviewed literature to cross the blood-brain barrier, which is why both are studied as centrally-active choline-donor research compounds relevant to acetylcholine synthesis and central nervous system research (Kansakar et al., Front Endocrinol 2023).

A 2023 systematic review and meta-analysis of 7 RCTs and 1 prospective cohort study reported that α-GPC combined with donepezil produced a mean difference of +1.72 (95% CI 0.20 to 3.25) on cognition scores versus donepezil alone, with mean differences of +0.79 (functional outcomes) and −7.61 (behavioral outcomes). Patients receiving α-GPC alone had significantly better cognition than those receiving placebo or other medications (MD +3.50, 95% CI 0.36 to 6.63) (Sagaro, Traini & Amenta, J Alzheimer’s Dis 2023).

An abstract in the resistance-exercise research literature reported that acute α-GPC supplementation raised peak growth hormone approximately 44-fold versus placebo baseline (from 0.19 ± 0.06 to 8.4 ± 2.1 ng/mL) in a resistance-exercise protocol (Ziegenfuss et al. 2008). A separate 2024 double-blind crossover trial did not detect a group difference in growth hormone at 315 or 630 mg (Kerksick, Nutrients 2024), so dose, timing, and cohort factors continue to be investigated.

The evidence is mixed. Early trials and preclinical models reported neuroprotection across multiple stages of the ischemic cascade (Gusev & Martynov 2015), but a 2023 pooled meta-analysis found that citicoline did not significantly improve NIHSS < 1 (OR 1.05, 95% CI 0.87–1.27) or mRS < 1 (OR 1.36, 95% CI 0.99–1.87) across acute-stroke RCTs (Sagaro & Amenta, J Clin Med 2023). Newer preclinical work continues to report SIRT1-mediated neuroprotection signaling (Hurtado 2013).

A 2021 matched cohort study of more than 12 million Korean adults aged 50+ without underlying stroke, Alzheimer’s, or cerebrovascular disease reported that α-GPC use was associated with a dose-dependent +46% higher 10-year stroke hazard versus non-users (Lee et al., JAMA Netw Open 2021). A preclinical mouse study reported that dietary α-GPC promoted atherosclerosis and elevated TMAO-producing gut bacteria (Zhao et al., IJMS 2021). Both findings are observational/preclinical and remain subjects of ongoing research.

Yes. Both are studied as centrally-acting choline donors relevant to acetylcholine synthesis, and both appear in cognitive research contexts, particularly in aging and vascular cognitive decline populations. Reviews of the choline-supplement literature discuss them side-by-side as cholinergic-pathway research materials (Kansakar et al. 2023).

Alpha GPC. The published record on Alpha GPC in athletic and resistance-exercise populations includes work on growth hormone response, isometric force production, countermovement jump velocity and mechanical power, and psychomotor performance (Ziegenfuss 2008; Bellar 2015; Marcus 2017). CDP-Choline is not a primary focus in this domain.

Alpha GPC contributes via its glycerophosphate fraction after cleaving off choline. CDP-Choline enters phospholipid synthesis more directly: cytidine is converted to uridine and then to UTP, which participates in the Kennedy pathway of phosphatidylcholine biosynthesis. This is why the CDP-Choline literature more heavily emphasizes membrane-repair and brain energy metabolism endpoints (Adibhatla & Hatcher, Neurochem Res 2005).

Yes — a 2023 systematic review and meta-analysis directly compared both compounds as choline-containing phospholipids in acute stroke research (Sagaro & Amenta, J Clin Med 2023). Both compounds also appear side-by-side in general choline-supplement reviews (Kansakar et al. 2023) and in reviews of choline-containing phospholipids in the neurovascular unit (Roy et al., Front Cell Neurosci 2022).

Alpha GPC has been examined in Alzheimer’s disease and vascular dementia research more than in Parkinson’s. A narrative review notes preclinical Parkinson’s-related work on α-GPC alongside Alzheimer’s and vascular dementia (Putri et al., Neuropsychiatr Dis Treat 2026). CDP-Choline has a comparatively larger footprint in Parkinson’s and glaucoma research literature.

No. Modern Aminos supplies Alpha GPC and CDP-Choline strictly as laboratory research materials. They are not for human consumption, not for veterinary use, and are not intended to diagnose, treat, cure, or prevent any disease.

Every Modern Aminos catalog item — including Alpha GPC 400MG and CDP-Choline (Citicoline) 500MG — carries a batch-specific Certificate of Analysis with a QR-code-verifiable batch number. Details are documented on the Modern Aminos Quality Assurance Program page.

The related monographs are available at Alpha GPC: What It Is, How It Works, and What Research Shows and CDP-Choline (Citicoline): What It Is, How It Works, and What Research Shows. Additional research-grade liquid amino blends are listed at Modern Aminos Liquid Amino Acid Blends.